NCT03658473 - Evaluation of Rebamipide and Rabeprazole Effect Associated or Not to Prevent Naproxen-induced Gastric Lesions | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 12, 2014

Primary Completion Date

November 27, 2014

Study Completion Date

February 4, 2015

Conditions

Gastric Lesion

Interventions

DRUG

550 mg naproxen + 300 mg rebamipide + 20 mg rabeprazole.

Oral administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + 20 mg rabeprazole 1x daily over 7 days.

DRUG

550 mg naproxen + placebo + 20 mg rabeprazole

Oral administration of 550 mg naproxen 2x daily + placebo of rebamipide 2x daily + 20 mg rabeprazole 1x daily over 7 days.

DRUG

550 mg naproxen + 300 mg rebamipide + placebo

Oral administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + placebo of rabeprazole 1x daily over 7 days.

DRUG

550 mg naproxen + placebo + placebo

Oral administration of 550 mg naproxen 2x daily + placebo 2x daily + placebo of rabeprazole 1x daily over 7 days.

Trial Locations (1)

Galeno Desenvolvimento de Pesquisas Clinicas Ltda., Campinas